Table 3 Summary of outcomes from SBRT trials with a follow-up of more than 30 months and at least 40 enrolled patients
Study | Schedule | # of patients | Risk class | Medi F/U (mos) | Late grade 3 GU toxicity | Late grade 3 GI toxicity | FFBF |
|---|---|---|---|---|---|---|---|
CyberKnife | |||||||
Katz et al. 2010 [5] | 35 – 36.25 Gy in 5 fx | 304 | L-I-H | 48 | 2% | - | 97, 93, 75% at 4 year |
Freeman, King, 2011. [6] | 7-7.25 Gy in 5 fx | 41 | L | 60 | < 1% | - | 93% at 5 year |
McBride et al. 2012 [7] | 36.25-37.5 Gy in 5 fx | 45 | L | 44.5 | < 1% | - | 97.7% at 3 years |
Fuller et al. [8] | 38 Gy in 4 fx † | 54 | L-I | 36 | 4% | - | 96% at 3 years |
Kang et al. [9] | 32-36 Gy in 4 fx | 44 | L-I-H | 40 | - | - | 100%, 100%, 90.9% at 5 years |
King et al. 2012 [10] | 36.25 Gy in 5 fx | 67 | L | 32.4 | 3.5% | - | 94% at 4 years |
Gantry-based Systems | |||||||
Madsen et al. 2007 [11] | 33.5 Gy in 5 fx | 40 | L | 41 | - | - | 90% at 4 years |
Boike et al. 2011 [12] | 45-50 Gy in 5 fx | 45 | L-I | 30, 18, 12 | 4% | 2% plus 1 Grade 4 | 100% at 1–2.5 years |